Cjc-1295 Dac Legal
In the United States, CJC-1295 DAC is fully legal to purchase, possess, and utilize strictly as an unapproved research chemical for non-clinical laboratory experiments. It is not a controlled substance under federal law, but it is not approved by the FDA for human consumption, clinical treatment, or veterinary use.
Quick answer
In the United States, CJC-1295 DAC is fully legal to purchase, possess, and utilize strictly as an unapproved research chemical for non-clinical laboratory experiments. It is not a controlled substance under federal law, but it is not approved by the FDA for human consumption, clinical treatment, or veterinary use.
Key takeaways
- Navigating the legal framework surrounding synthetic peptides requires a clear distinction between clinical therapeutics and laboratory research reagents.
- [CJC-1295](/research-peptides/cjc-1295-no-dac) DAC is a synthetic 29-amino-acid peptide derivative of human growth hormone-releasing hormone (GHRH, specifically GHRH 1-29).
- The primary mechanism of action for [CJC-1295](/research-peptides/cjc-1295-no-dac) DAC centers on its selective agonism at the Growth Hormone-Releasing Hormone Receptor (GHRH-R), a G-protein-coupled receptor located on the somatotroph cells of the anterior pituitary gland.
- Preclinical studies evaluating [CJC-1295](/research-peptides/cjc-1295-no-dac) DAC have focused predominantly on its capability to alter baseline somatotrophic axis output without entirely blunting natural pulsatile feedback loops.
Regulatory Classification and Legal Status of CJC-1295 DAC
Navigating the legal framework surrounding synthetic peptides requires a clear distinction between clinical therapeutics and laboratory research reagents. Under current United States federal law, CJC-1295 with Drug Affinity Complex (DAC) is classified as an unapproved investigational research chemical. It is not listed as a scheduled substance under the Controlled Substances Act (CSA), making the acquisition and possession of cjc-1295 dac legal for qualified research institutions, universities, and independent laboratories conducted strictly for *in vitro* or animal experimentation.
However, because CJC-1295 DAC has not received regulatory approval from the U.S. Food and Drug Administration (FDA) for human clinical use, its sale is restricted exclusively to laboratory research applications. Vendor distribution must comply with federal labeling regulations, explicitly identifying the material as a research compound not intended for diagnostic, therapeutic, or human use. Principal investigators and laboratory procurement officers must ensure that reagents obtained for research projects remain strictly within controlled experimental environments to comply with federal and institutional oversight regulations.
Chemical Architecture and the Drug Affinity Complex (DAC)
CJC-1295 DAC is a synthetic 29-amino-acid peptide derivative of human growth hormone-releasing hormone (GHRH, specifically GHRH 1-29). Native GHRH undergoes rapid enzymatic degradation in biological systems, primarily cleaved by dipeptidyl peptidase IV (DPP-IV) between the second and third amino acid residues (Alanine-Aspartate). To overcome this kinetic limitation in experimental models, chemical modifications were introduced, substituting specific amino acids to improve enzymatic resistance while retaining affinity for the GHRH receptor.
The defining modification in this compound is the covalent addition of the Drug Affinity Complex (DAC) modification via a lysine linker at the C-terminus. The DAC moiety consists of a reactive maleimido derivative (specifically 3-maleimidopropionic acid) that selectively binds to circulating serum albumin upon administration in animal models. By forming a stable, covalent bioconjugate with endogenous albumin, the molecular weight of the complex increases dramatically, preventing rapid renal clearance and protecting the peptide chain from cleavage. Researchers evaluating the CJC-1295 DAC peptide utilize this modification to extend biological half-life from minutes to several days in rodent and non-human primate models.
GHRH Receptor Binding Dynamics and Endocrine Mechanisms
The primary mechanism of action for CJC-1295 DAC centers on its selective agonism at the Growth Hormone-Releasing Hormone Receptor (GHRH-R), a G-protein-coupled receptor located on the somatotroph cells of the anterior pituitary gland. Upon ligand binding, GHRH-R activates the Gs alpha subunit, stimulating transmembrane adenylyl cyclase activity. This cascade elevates intracellular cyclic adenosine monophosphate (cAMP) concentrations, activating protein kinase A (PKA) pathways.
In preclinical laboratory settings, PKA activation leads to the phosphorylation of transcription factors such as CREB, facilitating both the immediate exocytosis of stored growth hormone (GH) and the long-term transcriptional upregulation of the GH gene. Unlike pulsatile native GHRH, the prolonged systemic presence of albumin-bound CJC-1295 DAC maintains sustained signal transduction at the pituitary level, leading to prolonged basal elevations in serum growth hormone levels and secondary stimulation of hepatic insulin-like growth factor 1 (IGF-1) synthesis. Investigating these cascades provides valuable insights within our broader research peptide library.
Preclinical Research Findings: GH Secretion and Tissue Repair Models
Preclinical studies evaluating CJC-1295 DAC have focused predominantly on its capability to alter baseline somatotrophic axis output without entirely blunting natural pulsatile feedback loops. In animal models, a single dose of CJC-1295 DAC demonstrated sustained increases in plasma GH and IGF-1 concentrations for up to 6 to 8 days. This extended pharmacokinetic profile allows investigators to study downstream metabolic effects, such as nitrogen retention, enhanced protein synthesis, and lipid oxidation, without requiring frequent dosing schedules.
Furthermore, rodent models assessing cellular repair and wound healing paradigms suggest that chronic elevation of IGF-1 secondary to GHRH receptor stimulation accelerates collagen deposition, cellular proliferation, and extracellular matrix remodeling. In vitro assays using muscle precursor cells (satellite cells) demonstrate increased mitotic activity when exposed to media derived from models treated with GHRH agonists, providing foundational data for musculoskeletal repair research.
Comparative Analysis: CJC-1295 DAC vs. Non-DAC and Related Secretagogues
When designing protocols for somatotroph axis investigation, researchers frequently contrast CJC-1295 DAC with alternative secretagogues to isolate specific kinetic effects. The fundamental structural difference between CJC-1295 DAC and CJC-1295 No DAC (often referred to as Modified GRF 1-29) is the presence of the maleimidopropionic acid reactive group. While CJC-1295 DAC exhibits a half-life measured in days due to albumin conjugation, Modified GRF 1-29 displays an elimination half-life of approximately 30 minutes in animal models, resulting in sharp, transient GH spikes rather than elevated baseline levels.
In addition to GHRH analogs, laboratories frequently study growth hormone secretagogues operating through parallel pathways, such as ghrelin receptor (GHSR-1a) agonists. For instance, combining a GHRH agonist with a growth hormone secretagogue like Ipamorelin, Sermorelin, or GHRP-2 generates a synergistic release of growth hormone in pituitary cell culture models. Understanding these distinctions allows investigators to select the appropriate compound class based on whether their experimental model requires continuous basal receptor activation or acute pulsatile stimulation within the broader category of growth hormone secretagogues.
Laboratory Reconstitution, Stability, and Storage Protocols
Maintaining structural integrity and preventing chemical degradation is vital when handling synthetic peptides in a laboratory setting. Lyophilized CJC-1295 DAC should be stored in a controlled freezer at -20°C or -80°C upon receipt to maintain long-term stability. Unopened vials kept at these sub-zero temperatures remain stable for up to 24 months, protected from light and moisture ingress.
When preparing the compound for *in vitro* or animal studies, reconstitution must be conducted under aseptic conditions within a laminar flow hood. Bacteriostatic water (0.9% benzyl alcohol) or sterile endotoxin-free water should be introduced slowly down the inner glass wall of the vial to prevent shearing forces. The vial should be gently swirled rather than vigorously shaken. Once reconstituted, liquid solutions are stable at 2°C to 8°C for up to 30 days. To avoid freeze-thaw cycles—which cause physical cleavage and aggregation—reconstituted solutions intended for long-term study should be aliquoted into single-use polypropylene tubes and stored at -80°C.
Analytical Purity Verification: HPLC, Mass Spectrometry, and Endotoxin Testing
Reliable scientific outcome metrics depend entirely on the chemical purity and consistency of research reagents. Impurities such as truncated peptide sequences, organic solvents, or bacterial endotoxins can confound experimental data and induce non-specific cellular toxicity. Therefore, every lot of CJC-1295 DAC must undergo rigorous multi-step analytical verification before distribution.
Purity assessment requires Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), which separates the target 29-amino-acid conjugated sequence from synthesis byproducts, ensuring a purity profile equal to or exceeding 99%. Matrix-Assisted Laser Desorption/Ionization or Electrospray Ionization Mass Spectrometry (ESI-MS) is simultaneously performed to verify exact molecular weight and sequence identity. Additionally, because bacterial lipopolysaccharides (LPS) can cause inflammatory signaling in cell cultures or animal models, quantitative Limulus Amebocyte Lysate (LAL) testing must confirm that bacterial endotoxin levels remain strictly under 0.01 EU/mg.
PX1 Research Quality Standards and Sourcing Assurance
PX1 Research operates as a primary supplier dedicated exclusively to supporting academic institutions, biotechnology firms, and private laboratories. All compounds in our inventory are USA-manufactured within state-of-the-art, GMP-compliant facilities adhering to ISO 9001 and ISO 17025 quality management frameworks. We enforce stringent quality control protocols to eliminate lot-to-lot variability and guarantee chemical precision.
Every batch of CJC-1295 DAC is accompanied by a comprehensive, lot-specific Certificate of Analysis (COA) issued by an independent ISO 17025 accredited third-party testing laboratory. These reports provide full transparency, including raw HPLC chromatograms, mass spectral analysis, and verified endotoxin measurements. Orders are packed under temperature-monitored conditions and shipped same-day (Monday through Friday) directly from our distribution centers in California and Arizona. Laboratory procurement teams looking to establish recurring supply chains can apply for bulk research accounts to access specialized logistics support.
Frequently Asked Questions
Is CJC-1295 DAC legal to buy for laboratory research in the US?
Yes. CJC-1295 DAC is legal to purchase, possess, and utilize in the United States strictly as an unapproved research chemical for non-clinical laboratory and analytical applications.
Is CJC-1295 DAC approved by the FDA?
No. CJC-1295 DAC is an investigational peptide that is not approved by the FDA for human consumption, clinical treatment, medical diagnosis, or veterinary use.
What is the primary structural difference between CJC-1295 DAC and CJC-1295 No DAC?
CJC-1295 DAC includes a Drug Affinity Complex modification (maleimidopropionic acid linker) that covalently binds to circulating serum albumin, extending its biological half-life to several days, whereas CJC-1295 No DAC lacks this complex and has a half-life of roughly 30 minutes.
How should lyophilized CJC-1295 DAC be stored in the lab?
Unopened, lyophilized vials should be stored at -20°C or -80°C away from light. Under these conditions, the peptide remains stable for up to 24 months.
What solvent is recommended for reconstituting CJC-1295 DAC for research?
Reconstitution is typically performed using sterile bacteriostatic water (0.9% benzyl alcohol) or sterile endotoxin-free water under aseptic conditions in a laminar flow hood.
How does PX1 Research verify the purity of CJC-1295 DAC?
Every lot undergoes independent third-party analytical testing using RP-HPLC to confirm >99% chemical purity, Mass Spectrometry (ESI-MS) to confirm molecular weight, and LAL assays to ensure endotoxin levels are below 0.01 EU/mg.
What biological targets does CJC-1295 DAC act upon in research models?
CJC-1295 DAC acts as a selective agonist at the Growth Hormone-Releasing Hormone Receptor (GHRH-R) on pituitary somatotrophs, activating the cAMP/PKA pathway to stimulate growth hormone release.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.